Delaware
|
001-34079
|
11-3516358
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
15245 Shady Grove Road, Suite 455
Rockville, MD |
20850
|
|
(Address of principal executive offices)
|
(Zip Code)
|
☒ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, $.0001 par value
|
REXN
|
Nasdaq Capital Market
|
Item 5.02 |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
Item 5.07
|
Submission of Matters to a Vote of Security Holders.
|
For
|
Against
|
Abstentions
|
Broker Non-Votes
|
1,497,055
|
116,477
|
24,543
|
1,700,158
|
For
|
Against
|
Abstentions
|
Broker Non-Votes
|
2,915,886
|
393,063
|
29,284
|
-
|
For
|
Against
|
Abstentions
|
Broker Non-Votes
|
3,086,313
|
212,300
|
39,617
|
-
|
For
|
Against
|
Abstentions
|
Broker Non-Votes
|
990,782
|
615,853
|
31,440
|
1,700,158
|
For
|
Against
|
Abstentions
|
Broker Non-Votes
|
1,461,486
|
150,381
|
26,208
|
1,700,158
|
For
|
Against
|
Abstentions
|
Broker Non-Votes
|
2,990,636
|
309,556
|
38,041
|
-
|
Item 8.01
|
Other Events.
|
Item 9.01
|
Financial Statements and Exhibits.
|
Exhibit
|
Description
|
Press release issued by Rexahn Pharmaceuticals, Inc. dated November 2, 2020.
|
REXAHN PHARMACEUTICALS, INC.
|
||
Date: November 3, 2020
|
/s/ Douglas J. Swirsky
|
|
Douglas J. Swirsky
|
||
President and Chief Executive Officer
|